Literature DB >> 8275683

The estimation of population pharmacokinetic parameters using an EM algorithm.

L Aarons1.   

Abstract

An EM algorithm was used to analyse data arising from non-linear mixed-effects models. The fixed parameters were determined by maximum likelihood using simplex minimization, and the random effects were estimated using the EM algorithm after linearization with respect to the random effects. Applications to a simple linear model and population pharmacokinetics are described. The use of posterior parameter estimates to investigate covariate relationships is briefly described. The implementation of the estimation-maximization (EM) algorithm described here has proved in practice to be robust but slow. We intend to use a Newton-Raphson minimization routine in place of the simplex method to hasten convergence. The alternative linearization of the non-linear mixed effects model suggested by Lindstrom and Bates (Biometrics 46 (1990) 673-687) is much more unstable than the usual linearization, especially during the initial iterations. In the case of indomethacin the two linearizations produced very similar results. The individual posterior parameter estimates provided by the program are very useful for the detection of covariate relationships in population pharmacokinetic studies. In addition, the posterior means can be used in the estimation of pharmacokinetic-pharmacodynamic relationships from sparse pharmacokinetic data where individual modelling is impossible.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8275683     DOI: 10.1016/0169-2607(93)90062-p

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  9 in total

1.  A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients.

Authors:  L Evans; L Aarons; P Coates
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

Review 2.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

Review 3.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

4.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

5.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

Review 6.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

7.  Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes.

Authors:  F Bressolle; M Audran; R Gareau; T N Pham; R Gomeni
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

8.  A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients.

Authors:  Kayode Ogungbenro; Lakshmi Vasist; Robert Maclaren; George Dukes; Malcolm Young; Leon Aarons
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

9.  Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models.

Authors:  Henrik Bjugård Nyberg; Andrew C Hooker; Robert J Bauer; Yasunori Aoki
Journal:  AAPS J       Date:  2020-07-02       Impact factor: 4.009

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.